AR094879A1 - Formulación oral y suspensión de un fármaco oncológico - Google Patents

Formulación oral y suspensión de un fármaco oncológico

Info

Publication number
AR094879A1
AR094879A1 ARP140100584A ARP140100584A AR094879A1 AR 094879 A1 AR094879 A1 AR 094879A1 AR P140100584 A ARP140100584 A AR P140100584A AR P140100584 A ARP140100584 A AR P140100584A AR 094879 A1 AR094879 A1 AR 094879A1
Authority
AR
Argentina
Prior art keywords
suspension
oral formulation
oncological drug
oncological
drug
Prior art date
Application number
ARP140100584A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR094879A1 publication Critical patent/AR094879A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mechanical Engineering (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Formulación oral y suspensión de una composición farmacéutica que comprende sonidegib que es útil para tratar enfermedades relacionadas con la actividad de la vía de señalización del Erizo que incluyen, por ejemplo, cánceres del cerebro, músculo, piel y próstata; meduloblastoma; adenocarcinomas pancreáticos; y carcinomas de pulmón de células pequeñas.
ARP140100584A 2013-02-25 2014-02-25 Formulación oral y suspensión de un fármaco oncológico AR094879A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361768803P 2013-02-25 2013-02-25

Publications (1)

Publication Number Publication Date
AR094879A1 true AR094879A1 (es) 2015-09-02

Family

ID=50288200

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100584A AR094879A1 (es) 2013-02-25 2014-02-25 Formulación oral y suspensión de un fármaco oncológico

Country Status (11)

Country Link
US (2) US9943520B2 (es)
EP (1) EP2958550B1 (es)
JP (1) JP6310484B2 (es)
AR (1) AR094879A1 (es)
AU (1) AU2014220339B2 (es)
ES (1) ES2935528T3 (es)
IL (2) IL240629B (es)
PL (1) PL2958550T3 (es)
TW (2) TWI684462B (es)
WO (1) WO2014128661A1 (es)
ZA (1) ZA201506012B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016155630A1 (zh) * 2015-03-30 2016-10-06 苏州晶云药物科技有限公司 N-[6-(顺式-2,6-二甲基吗啉-4-基)吡啶-3-基]-2-甲基-4'-(三氟甲氧基)[1,1'-联苯]-3-甲酰胺单磷酸盐的晶型及其制备方法
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof
CN116327772B (zh) * 2021-12-22 2025-05-16 中国科学院上海营养与健康研究所 SMO抑制剂Sonidegib对管腔型乳腺癌骨转移的靶向治疗方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
JO2889B1 (en) * 2008-09-17 2015-03-15 نوفارتيس ايه جي Salts 6N - (CIS-2, 6-dimethyl morpholine-4-yl) pyridine-3-yl-methyl-4 ’- (tetrafluoromethoxy) [1,1,-2-phenyl] -3-carboxamide
AR077490A1 (es) * 2009-07-21 2011-08-31 Novartis Ag Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel
US8927718B2 (en) * 2009-08-26 2015-01-06 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
JP2012094104A (ja) * 2010-09-29 2012-05-17 Omron Corp 情報処理装置および方法、並びにプログラム

Also Published As

Publication number Publication date
TW201442738A (zh) 2014-11-16
EP2958550B1 (en) 2022-08-17
IL276838B (en) 2021-05-31
ES2935528T3 (es) 2023-03-07
JP6310484B2 (ja) 2018-04-11
US20160008369A1 (en) 2016-01-14
WO2014128661A1 (en) 2014-08-28
JP2016510724A (ja) 2016-04-11
US9943520B2 (en) 2018-04-17
IL240629B (en) 2020-09-30
AU2014220339B2 (en) 2016-12-01
US20180071305A1 (en) 2018-03-15
PL2958550T3 (pl) 2023-01-16
ZA201506012B (en) 2020-01-29
EP2958550A1 (en) 2015-12-30
TWI684462B (zh) 2020-02-11
AU2014220339A1 (en) 2015-09-17
US10426781B2 (en) 2019-10-01
TWI696470B (zh) 2020-06-21
TW202019392A (zh) 2020-06-01
IL276838A (en) 2020-10-29
IL240629A0 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
NI201600071A (es) Compuestos de inhibidor de autotaxina
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
CR20140108A (es) Compuesto de ciclopropanoamina
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX380273B (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
MX2015010724A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
MX2019006878A (es) Uso de flecainida como un agente anti-conexina y metodo para potenciar los efectos de un farmaco psicotropico.
AR090774A1 (es) Dihidrato de un compuesto de benzotiofeno o de una de sus sales y proceso para su produccion
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2016000480A (es) Composiciones farmaceuticas de pancreatina de alta potencia.
MX395492B (es) Usos terapeuticos de l-4 cloroquinurenina.
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
DOP2015000290A (es) Benzoxazoles sustituidos
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.

Legal Events

Date Code Title Description
FC Refusal